Search results for: 'cell ad gene manufacturing'

The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...

23 Oct 2020  |  Global  |  Market Research

Supply Chain Optimization and Decentralized Manufacturing to Expand the Contract Cell and Gene Therapy Manufacturing Market, 2020–2026

Automation Deployed to Contain Cost of Goods Sold and Vector Manufacturing Standardization will Create New Growth Opportunities

Infographics

×

The cell and gene therapy segment is one of the fastest growing segments in the biopharmaceutical space. While the science behind the therapy has grown by leaps and bounds on the back of decades worth of research, manufacturing has unfortunately lagged behind. To fully harness the curative potential of these therapies and ensure greater reach and a...

With the growing need for better therapeutics, and the current patent cliff that is underway, therapies such as monoclonal antibodies, recombinant protein therapeutics and even vaccines for a whole host of indications are in high demand. Conventionally expression systems were utilized to aid in the development and production of these therapeutics...

This research identifies some the key developments across CAR-T cell therapies and provides insights across technological, IP, and investment landscapes. The study also provides an analysis of the competitive landscape while highlighting the key growth opportunities within the CAR-T cell therapy platform.

10 May 2023  |  Global  |  Market Research

Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector

Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential

Infographics

×

This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe; and Asia-Pacific (APAC). The report offers a detailed segment analysis of...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

02 Sep 2015  |  Global  |  Market Research

The New Age of Regenerative Medicine

Why Stem Cell Therapy?

Infographics

×

Cell therapy is the fastest growing segment of the Regenerative Medicine (RM) industry. It comprises both immune cell therapy and stem cell therapy; however, stem cell therapy makes up the largest part of this segment. The global cell therapy market is driven by the success of stem cell treatments in treating or curing life-threatening diseases suc...

Since the advent of stem cells reprogramming after the discovery of the differentiation factors that allow the creation of human induced pluripotent stem cells, researchers all around the world are strongly committed to develop novel methods to design and build human stem cells. Indeed, there is an increasing demand for the more efficient product...

This study investigates the global stem cell market for the period 2013 to 2018. The geographic regions covered in the study are the North America, Europe and APAC, followed by a detailed Asia Pacific Region Analysis, which covers countries such as India, Australia, Thailand, Singapore, South Korea, Malaysia and Japan. The stem cell market is cover...